About Urovant

Our Mission

Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.

Urovant’s lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

We have initiated an international Phase 3 program for vibegron. We also intend to expand our pipeline in urologic diseases in the future.


Copyright 2018 © All Rights Reserved